重要なことは経験です。 その理由をご覧ください。
お気軽にお問い合わせください。
Clinical Trials & REMS in the Time of Corona: FDA & MHRA Advice and Guidance
Pharmacovigilance expert Bart Cobert discusses the FDA and MHRA guidance for non-Corona related clinical trials.
Read More
Does Rapid FDA Approval Produce Drug Safety Issues?
Bart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.
Read More
Clintrials.gov Update
Bart Cobert on the importance of publishing clinical trials data and implications on pharmacovigilance.
Read More
Pharmacovigilance 2030
This is an interesting article looking at what PV will be in the year 2030.
Read More
FDA Draft Guidance on PMRs
Bart Cobert highlights the most important changes in the recently revised FDA draft guidance on PMRs.
Read More
Ranitidine – What Happened and What Do We Learn?
Bart Cobert explores several important points to take from the still ongoing signal and safety issue with Renitidine recall.
Read More
ビデオEメール： お客様満足度向上の秘密兵器
The advantages of utilizing video email response to overcome low customer satisfaction.
Read More
Why Coupons Are Still a Powerful Strategy for Brands
When it comes to driving consumer behavior, coupons continue to be a powerful force.
Read More
Going Mobile: Creating Experiences that Matter with the Avaya Mobile Experience
Read how C3i Solutions is leveraging Avaya Mobile Experience to provide better customer experience.
Read More
Vaping – A Serious Safety Signal
Bart Cobert discusses the major safety issue in the US on e-cigarettes and vaping.
Read More
